Review Article
The Molecular Blueprint for Chronic Obstructive Pulmonary Disease (COPD): A New Paradigm for Diagnosis and Therapeutics
Table 1
Pro-inflammatory signaling pathway inhibitors for COPD.
| S. no. | Inhibitor/drug | Mechanism/effect | Clinical progress | References |
| 1 | RV568 | P38MAPK pathway inhibitor | No effect (NCT01475292) (NCT01661244) | [135] |
| 2 | Nemiralisib (GSK2269557) | PI3K inhibitor | 28 Days treatment (NCT02294734) 84 Days treatment (NCT02522299) | [136] |
| 3 | RV1729 | PI3K inhibitor | Phase I Trial, limited efficacy (NCT02140346) | [136, 137] |
| 4 | VIP (vasoactive intestinal peptide) | Increases cAMP, adenylate cyclase, and phospholipase C | 3 Months inhaled treatment (NCT00464932) | [138, 139] |
| 5 | Adenosine A2A receptor (UK-432097) | cAMP enhancer | No effect (NCT00430300) | [140, 141] |
| 6 | AZD1981 | Prostaglandin D2 receptor inhibitor | No effect (NCT00690482) | [142] |
| 7 | Bimosiamose | Selectins inhibitor | 28 Days inhalation treatment (NCT01108913) | [143] |
|
|